# Rejoni

> Privately held, clinical-stage women's health medical device company in Bedford, Massachusetts
> (founded June 2020 by Amar Sawhney, PhD and Pramand LLC) developing proprietary hydrogel-based
> biomaterial therapies for gynecological surgery. Its lead product, the Juveena Hydrogel System, is
> designed to prevent the formation and reformation of intrauterine adhesions (IUAs) after
> transcervical procedures such as dilation and curettage or myomectomy. A low-profile transcervical
> catheter delivers two liquid precursors that cross-link into a soft, temporary hydrogel implant
> which separates the uterine walls during healing and resorbs in roughly two to three weeks — about
> one menstrual cycle — so no removal procedure is needed. Juveena is investigational only and
> pending FDA approval; the FDA filed the premarket approval (PMA) application in January 2026.

This file is generated by API Evangelist from the public profile at
https://github.com/api-evangelist/rejoni — Rejoni does not publish an llms.txt of its own.

## APIs

Rejoni publishes no public API, developer portal, API documentation, SDK, or machine-readable API
contract (OpenAPI, AsyncAPI, GraphQL, MCP, A2A) as of 2026-08-05. Probes of the corporate host for
/openapi.json, /swagger.json, /api-docs, /docs, /api, /graphql, /mcp, /llms.txt and every
/.well-known/ discovery path returned HTTP 404, verified against a control path so the 404s are real
rather than a soft-200 catch-all. api.rejoni.com, developer.rejoni.com, docs.rejoni.com,
app.rejoni.com and portal.rejoni.com resolve only to a wildcard A record with no listener answering
on port 80 or 443. Rejoni's product is a hydrogel implant and a transcervical delivery catheter —
a Class III medical device, not software with an interface a third party can call.

## Company

- [Website](https://rejoni.com/): Corporate site (Webflow)
- [About](https://rejoni.com/about): Founding, mission, and company overview
- [Technology](https://rejoni.com/technology): The Juveena Hydrogel System — precursors, catheter, resorption
- [Our Team](https://rejoni.com/team): Leadership
- [News & Events](https://rejoni.com/news): Press releases and conference appearances
- [Contact Us](https://rejoni.com/contact): info@rejoni.com — 201 Burlington Rd, Bedford, MA 01730, +1 781-222-0081
- [Privacy Statement](https://rejoni.com/privacy)
- [LinkedIn](https://www.linkedin.com/company/rejoni)
- [Forge Global](https://forgeglobal.com/rejoni_stock/): Secondary-market listing

## Recent announcements

- 2026-06-16: Rejoni secures $25 million in financing to accelerate the Juveena Hydrogel System toward FDA approval and launch — ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital, Sparta Group
- 2026-05-04: Rejoni appoints women's health MedTech leader John Nealon as chief executive officer
- 2026-01-13: FDA files Rejoni's Juveena Hydrogel System PMA for the prevention of intrauterine adhesions
- 2026-11-13: AAGL 2026 55th Annual Global Congress on MIGS (upcoming tradeshow)

## Artifacts

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/rejoni/refs/heads/main/apis.yml): APIs.json 0.20 profile
- [Domain security](https://raw.githubusercontent.com/api-evangelist/rejoni/refs/heads/main/security/rejoni-domain-security.yml): TLS/DNS/email-auth probe
- [Well-known probe](https://raw.githubusercontent.com/api-evangelist/rejoni/refs/heads/main/well-known/rejoni-well-known.yml): /.well-known/ and contract-discovery probe results